Ingmar Bruns's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 20,000 Common Stock done at an average price of $2.3 . Disclosure was reported to the exchange on Feb. 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | Ingmar Bruns | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 06 Feb 2025 | 20,000 | 36,629 | - | 2.3 | 45,656 | Common Stock |
| Zentalis Pharmaceuticals Inc | Ingmar Bruns | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 16,629 | 16,629 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Ingmar Bruns | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 16,629 | 16,629 | - | - | Stock Option (Right to Buy) |